HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities

The RV144 ALVAC/AIDSVax HIV-1 vaccine clinical trial showed an estimated vaccine efficacy of 31.2%. Viral genetic analysis identified a vaccine-induced site of immune pressure in the HIV-1 envelope (Env) variable region 2 (V2) focused on residue 169, which is included in the epitope recognized by va...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pollara, Justin, Bonsignori, Mattia, Moody, M. Anthony, Liu, Pinghuang, Alam, S. Munir, Hwang, Kwan-Ki, Gurley, Thaddeus C., Kozink, Daniel M., Armand, Lawrence C., Marshall, Dawn J., Whitesides, John F., Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Robb, Merlin L., O'Connell, Robert J., Kim, Jerome H., Michael, Nelson L., Montefiori, David C., Tomaras, Georgia D., Liao, Hua-Xin, Haynes, Barton F., Ferrari, Guido
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2014
Assuntos:
Vaccines and Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4097802/
https://ncbi.nlm.nih.gov/pubmed/24807721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00156-14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados